.

Deeper Knowledge, Faster

  • Uncover prior art in expired and abandoned patents
  • Obtain formulation and manufacturing information
  • Drug patents in 130+ countries

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Queensland Health
Cerilliant
Covington
Merck
Mallinckrodt
Fuji
Citi
Chinese Patent Office
Federal Trade Commission
AstraZeneca

Generated: November 21, 2017

DrugPatentWatch Database Preview

Details for Patent: 7,935,690

« Back to Dashboard

Which drugs does patent 7,935,690 protect, and when does it expire?


Patent 7,935,690 protects TESTIM and is included in one NDA. There has been one Paragraph IV challenge on Testim.

This patent has forty-five patent family members in twenty-nine countries.

Summary for Patent: 7,935,690

Title:Pharmaceutical composition
Abstract: A pharmaceutical composition comprising: (A) an androgen; (B) a cyclic enhancer of the type used in the compositions and methods claimed by U.S. Pat. No. 5,023,252 to Hsieh; and (C) a thickening agent; including, for example, a composition in which the cyclic enhancer is a macrocyclic ester or a macrocyclic ketone; the use of the composition to treat a condition, for example, male hypogonadism, in a patient by applying the composition to the membrane of the patient; and a method for making the composition.
Inventor(s): Gyurik; Robert J. (Exeter, NH)
Assignee: CPEX Pharmaceuticals, Inc. (Exeter, NH)
Application Number:11/928,467
Patent Claim Types:
see list of patent claims
Use; Composition; Delivery;

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use
Auxilium Pharms Llc
TESTIM
testosterone
GEL;TRANSDERMAL021454-001Oct 31, 2002AB2RXYesYes► Subscribe► Subscribe METHOD FOR ADMINISTRATION OF TESTOSTERONE
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Non-Orange Book Patents for Patent: 7,935,690

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
7,320,968Pharmaceutical composition► Subscribe
7,608,607Pharmaceutical composition► Subscribe
7,608,608Pharmaceutical composition► Subscribe
8,063,029Pharmaceutical composition► Subscribe
7,608,610Pharmaceutical composition► Subscribe
8,178,518Pharmaceutical composition► Subscribe
7,608,609Pharmaceutical composition► Subscribe
7,608,606Pharmaceutical composition► Subscribe
7,608,605Pharmaceutical composition► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Patent: 7,935,690

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Hong Kong1167332► Subscribe
European Patent Office1425019► Subscribe
Norway335864► Subscribe
New Zealand535970► Subscribe
Norway20045019► Subscribe
MexicoPA04010311► Subscribe
Malaysia139721► Subscribe
Taiwan200408397► Subscribe
Poland213976► Subscribe
Saudi Arabia1707► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the database preview and plans and pricing

Serving leading biopharmaceutical companies globally:

Federal Trade Commission
Cipla
Chubb
Citi
Novartis
Boehringer Ingelheim
McKinsey
Teva
AstraZeneca
Express Scripts

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot